PURPOSE: To evaluate the efficacy and safety of the @entity1205 - @entity900 combination in @entity1 with advanced @entity1149 ( @entity1149 ). @entity1 AND METHODS: Chemotherapy-na  ve @entity1 with histologically confirmed, measurable stage IIIB or IV @entity1149 , a World Health Organization (WHO) performance status of 0-2 and adequate bone marrow, @entity8 were eligible for the study. @entity1 received @entity1205 (100 mg/m2) as an one-hour infusion on day 1 and @entity900 (80 mg/m2) as a 30-min infusion with appropriate hydration on day 2. @entity1261 ( @entity1261 ; 150 micrograms/m2, SC) was given on days 3 to 13. Treatment was repeated every three weeks. RESULTS: Fifty-three @entity1 were enrolled (28 with stage IIIB and 25 with stage IV). One complete and 23 partial responses were observed (overall response rate (OR): 45%; 95% CI: 34.1%-61.8%). The response rate was 57% and 32% in @entity1 with stages IIIB and IV disease (P = NS). The median time to progression was 36 weeks and the median survival 48 weeks; the one-year survival was 48%. Grade 3-4 @entity1398 occurred in 23 @entity1 , 15 of whom were hospitalized for @entity221 ; two @entity1 died of @entity295 . Grade 2 @entity2359 was observed in six @entity1 and grade 3 in five @entity1 ; grade 3 @entity1295 occurred in seven @entity1 , grade 3-4 @entity33 in four @entity1 and grade 3-4 @entity294 in six @entity1 . Mild @entity56 and @entity4 were observed in five and four @entity1 , respectively. The median dose intensity was 30 mg/m2/week for @entity1205 and 24 mg/m2/week for @entity900 , corresponding to 91% and 89% of the specified protocol doses, respectively. CONCLUSIONS: The @entity1205 - @entity900 combination is an active regimen in advanced @entity1149 , but @entity1503 remains high despite the prophylactic use of @entity1261 .

First-line treatment of advanced @entity1149 with @entity1205 and XXXX : a multicenter phase II study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal, hepatic and cardiac function'] @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'Granulocyte colony-stimulating factor'] @entity221 :: ('MESH:D005334', 'Disease') :: ['neutropenic fever'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity4 :: ('MESH:D004487', 'Disease') :: ['oedema'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematologic toxicity'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic reactions'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxicity']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
